EXTH-45. THERAPEUTIC EFFICACY OF MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 WITH STANDARD THERAPY IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS

Mutation in isocitrate dehydrogenase 1 (IDH1) occurs in >70% of WHO grade II/III astrocytomas, oligodendrogliomas and secondary glioblastoma. The mutant enzyme catalyzes the reduction of α-ketoglutaric acid to D-2-hydroxyglutaric acid, leading to cancer initiation. In this study, we examined ther...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Kogiso, Mari, Qi, Lin, Zhang, Huiyuan, Braun, Frank, Du, Yuchen, Huang, Lei, Guo, Lei, Huang, Yulun, Lindsay, Holly B, Zhao, Sibo, Injac, Sarah, Baxter, Patricia, Su, Jack, Perlaky, Laszlo, Parsons, Williams, Chintagumpala, Murali, Adekunle, Adesina, Wang, Jialiang, Song, Yongcheng, Li, Xiao-Nan
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847717/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.377
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars